Crouzon Syndrome Treatment & Management
- Author: Lukasz Matusiak, MD, PhD; Chief Editor: Dirk M Elston, MD more...
Nonsurgical treatment of Crouzon syndrome has been performed using orthopedic and orthodontic devices, as well as prosthetic devices.[18, 19]
A neurosurgical procedure is recommended in cases of intracranial hypertension leading to further optic atrophy. This surgery is difficult, and the procedure must be considered and undertaken in stages.
Facial plastic surgery can be of great benefit. It is usually based on various craniofacial osteogenesis distraction methods and systems; patients usually wear a custom-fitted helmet (or cranial band) for several months after surgery.[5, 21, 22, 23, 24, 25, 26, 27] It is one of the few syndromes for which the cosmetic results of the surgery can be strikingly effective. The surgery minimizes the risk linked to the neurological complications, but also has an impact on stigmatization feelings, the psychological and social implications.
Consultations with ophthalmologists, laryngologists, neurologists, psychiatrists, and stomatologists are usually required.
Ignatowicz R, Gdakowicz B. [Craniofacial dysostosis of the Crouzon type]. Wiad Lek. 1971 Feb 15. 24(4):363-6. [Medline].
Maeda T, Hatakenaka M, Muta H, Nakayama M, Nakazaki Y, Hiroyama T, et al. Clinically mild, atypical, and aged craniofacial syndrome is diagnosed as Crouzon syndrome by identification of a point mutation in the fibroblast growth factor receptor 2 gene (FGFR2). Intern Med. 2004 May. 43(5):432-5. [Medline].
Miklaszewska M. Dysostosis cranio-facialis hederitaria. Miklaszewska M, Wasik F, eds. Dermatologia Pediatryczna. Wrocaw, Poland: Volumed; 2000. Vol 2: 650-4.
Miklaszewska M, Racawska A, Ziarkiewicz M. Syndroma Crouzon and syndromal acanthosis nigricans. Demonstration of case on the meeting of Polish Dermatological Society. February 1990.
Posnick JC, Ruiz RL. The craniofacial dysostosis syndromes: current surgical thinking and future directions. Cleft Palate Craniofac J. 2000 Sep. 37(5):433. [Medline].
Gines E, Rodriguez-Pichardo A, Jorquera E, Moreno JC, Camacho F. Crouzon disease with acanthosis nigricans and melanocytic nevi. Pediatr Dermatol. 1996 Jan-Feb. 13(1):18-21. [Medline].
Helman SN, Badhey A, Kadakia S, Myers E. Revisiting Crouzon syndrome: reviewing the background and management of a multifaceted disease. Oral Maxillofac Surg. 2014 Sep 24. [Medline].
Bodo M, Baroni T, Carinci F, Becchetti E, Conte C, Bellucci C, et al. Interleukin secretion, proteoglycan and procollagen alpha(1)(I) gene expression in Crouzon fibroblasts treated with basic fibroblast growth factor. Cytokine. 2000 Aug. 12(8):1280-3. [Medline].
Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci U S A. 2004 Aug 24. 101(34):12555-60. [Medline].
Kress W, Collmann H, Büsse M, Halliger-Keller B, Mueller CR. Clustering of FGFR2 gene mutations inpatients with Pfeiffer and Crouzon syndromes (FGFR2-associated craniosynostoses). Cytogenet Cell Genet. 2000. 91(1-4):134-7. [Medline].
Wilkes D, Rutland P, Pulleyn LJ, Reardon W, Moss C, Ellis JP, et al. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J Med Genet. 1996 Sep. 33(9):744-8. [Medline].
Schweitzer DN, Graham JM Jr, Lachman RS, Jabs EW, Okajima K, Przylepa KA, et al. Subtle radiographic findings of achondroplasia in patients with Crouzon syndrome with acanthosis nigricans due to an Ala391Glu substitution in FGFR3. Am J Med Genet. 2001 Jan 1. 98(1):75-91. [Medline].
Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995 Dec. 11(4):462-4. [Medline]. [Full Text].
Fenwick AL, Goos JA, Rankin J, Lord H, Lester T, Hoogeboom AJ, et al. Apparently synonymous substitutions in FGFR2 affect splicing and result in mild Crouzon syndrome. BMC Med Genet. 2014 Aug 31. 15:95. [Medline].
Cohen MM Jr. Let's call it "Crouzonodermoskeletal syndrome" so we won't be prisoners of our own conventional terminology. Am J Med Genet. 1999 May 7. 84(1):74. [Medline].
Ernyei S. Craniofacial dysplasia associated with congenital cataract, impairment of hearing and brachydactyly. Am J Ophthalmol. 1966 Oct. 62(4):697-702. [Medline].
Kowalski M, Paszkowska M, Bryjanowska L. [A case of Crouzon's syndrome with coexistance of other congenital anomalies (author's transl)]. Klin Oczna. 1977 Oct. 47(10):445-7. [Medline].
Maspero C, Giannini L, Galbiati G, Kairyte L, Farronato G. Non surgical treatment of Crouzon Syndrome. Stomatologija. 2014. 16(2):72-80. [Medline].
Rathee M, Tamrakar AK, Kundu R, Yunus N. Three-dimensional precise orientation of bilateral auricular trial prosthesis using a facebow for a young adult with Crouzon syndrome. BMJ Case Rep. 2014 Aug 5. 2014:[Medline].
Meling TR, Høgevold HE, Due-Tønnessen BJ, Skjelbred P. Comparison of perioperative morbidity after LeFort III and monobloc distraction osteogenesis. Br J Oral Maxillofac Surg. 2010 Mar 10. [Medline].
Opitz C, Ring P, Stoll C. Orthodontic and surgical treatment of patients with congenital unilateral and bilateral mandibulofacial dysostosis. J Orofac Orthop. 2004 Mar. 65(2):150-63. [Medline].
Scolozzi P, Herzog G, Jaques B. Simultaneous maxillo-mandibular distraction osteogenesis in hemifacial microsomia: a new technique using two distractors. Plast Reconstr Surg. 2006 Apr 15. 117(5):1530-41; discussion 1542. [Medline].
Tessier P. The definitive plastic surgical treatment of the severe facial deformities of craniofacial dysostosis. Crouzon's and Apert's diseases. Plast Reconstr Surg. 1971 Nov. 48(5):419-42. [Medline].
Kobayashi S, Nishiouri T, Maegawa J, Hirakawa T, Fukawa T. A novel craniofacial osteogenesis distraction system enabling control of distraction distance and vector for the treatment of syndromic craniosynostosis. J Craniofac Surg. 2012 Mar. 23(2):422-5. [Medline].
Ko EW, Chen PK, Tai IC, Huang CS. Fronto-facial monobloc distraction in syndromic craniosynostosis. Three-dimensional evaluation of treatment outcome and facial growth. Int J Oral Maxillofac Surg. 2012 Jan. 41(1):20-7. [Medline].
Nakajima H, Sakamoto Y, Tamada I, Ohara H, Kishi K. An internal distraction device for Le Fort distraction osteogenesis: the NAVID system. J Plast Reconstr Aesthet Surg. 2012 Jan. 65(1):61-7. [Medline].
Kuroda S, Watanabe K, Ishimoto K, Nakanishi H, Moriyama K, Tanaka E. Long-term stability of LeFort III distraction osteogenesis with a rigid external distraction device in a patient with Crouzon syndrome. Am J Orthod Dentofacial Orthop. 2011 Oct. 140(4):550-61. [Medline].
Bemmels H, Biesecker B, Loewenstein J, Krokosky A, Guidotti R, Sutton EJ. Psychological and Social Factors in Undergoing Reconstructive Surgery Among Individuals with Craniofacial Conditions: An Exploratory Study. Cleft Palate Craniofac J. 2012 Feb 8. [Medline].